Results 111 to 120 of about 3,353 (184)

Molecular determinants associated with resistance to imipenem and imipenem-relebactam in clinical Pseudomonas aeruginosa isolates. [PDF]

BMC Genomics
Lorusso AB, de Souza J, Bail L, Ito CAS, Carrara JA, Tuon FFB, Faoro H.   +6 more
europepmc   +1 more source

Global epidemiology of carbapenem-resistant <i>Pseudomonas aeruginosa</i>. [PDF]

JAC Antimicrob Resist
Gottesdiener LS, Satlin MJ.
europepmc   +1 more source

Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1. [PDF]

J Antimicrob Chemother
Raro OHF, Mancini S, Findlay J, Seth-Smith HMB, Ali Syed M, Egli A, Nordmann P, Poirel L.   +7 more
europepmc   +1 more source

Development of a novel LC-MS/MS method for concurrent determination of imipenem, relebactam, and cilastatin in human serum, urine and peritoneal drainage fluid. [PDF]

BMC Chem
Yang X, Zhao C, Ding Y, Li Y, Zhao Y, Lin W, Li J, Wang D, Yue Z, Pei L, Jia M, Cao LL, Wang H.   +12 more
europepmc   +1 more source

Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis. [PDF]

Mediterr J Hematol Infect Dis
Marzi F, Alessandri M, De Crescenzo V, Del Vecchio S, Radi S, Manini M.   +5 more
europepmc   +1 more source

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +2 more sources

Comparative evaluation of the activity of novel β-lactam antibiotics against difficult-to-treat <i>Pseudomonas aeruginosa</i> clinical isolates. [PDF]

JAC Antimicrob Resist
Mystakelis H, Shields RK, Mathers AJ, Bergman Y, Munita JM, Cosgrove SE, Simner PJ, Tamma PD.   +7 more
europepmc   +1 more source

<i>In vitro</i> activity of imipenem-relebactam against carbapenem-resistant <i>Pseudomonas aeruginosa</i>: correlation with carbapenem MICs and association with <i>β</i>-lactamase classes. [PDF]

Front Microbiol
Alsharidi AI, Alhumaidi RA, Albarrag AM, Al-Tawfiq JA, Somily AM.   +4 more
europepmc   +1 more source

Data-driven design and screening of novel <i>Klebsiella pneumoniae</i> carbapenemase-2 β-lactamase inhibitors using a generative CLM. [PDF]

RSC Adv
Tariq SS, Haleem MS, Uddin R.
europepmc   +1 more source

Determining the Activity of Imipenem/Relebactam Plus Aztreonam Against Constitutive <i>Pseudomonas</i>-Derived Cephalosporinase- and Metallo-β-Lactamase-Producing <i>Pseudomonas aeruginosa</i> in a Hollow Fiber Infection Model. [PDF]

Open Forum Infect Dis
O'Donnell JN, Moolick KE, Nahorniak AI, Gifford MJ, Young K, Lodise TP.   +5 more
europepmc   +1 more source